Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)

NCT01444417 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01444417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01444417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2012
Completion date
February 28, 2015
Enrollment
62 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic thrombocytopenic purpura, immune thrombocytopenia, thrombocytopenia, thrombocytopenia in pediatric subjects with immune (idiopathic) thrombocytopenic purpura (itp), thrombocytopenia in subjects with immune (idiopathic) thrombocytopenic purpura (itp), thrombocytopenic purpura